Second-line Therapies; Antibody Alone Subsumes Rituximab, Alemtuzumab, Obinutuzumab, Ofatumumab; Ibrutinib or Idelalisib Subsume Ibrutinib, BRI vs BR + Placebo, CLL2BIG Study, Idelalisib and Idelalisib + Rituximab; Lenalidomide Subsumes Lenalidomide and BRL